3-(2-BROMOPHENYLIMINO)-4-THIA-1,2,9-TRIAZASPIRO[4.15]ICOS-1-EN-10-ONE


Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	PEYQMRWMCSCAAO-DAFNUICNSA-N
Smiles	Brc1ccccc1\N=C\2/SC3(CCCCCCCCCCC(=O)NCCC3)N=N2
InChI	InChI=1S/C22H31BrN4OS/c23-18-12-8-9-13-19(18)25-21-26-27-22(29-21)15-10-6-4-2-1-3-5-7-14-20(28)24-17-11-16-22/h8-9,12-13H,1-7,10-11,14-17H2,(H,24,28)/b25-21-

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C22H31BrN4OS
Molecular Weight	479.48
AlogP	7.84
Hydrogen Bond Acceptor	5.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	1.0
Polar Surface Area	91.48
Molecular species	NEUTRAL
Aromatic Rings	1.0
Heavy Atoms	29.0

Assay Description	Organism	Bioactivity
Antifungal activity against Phomopsis asparagi by mycelium growth rate test	Phomopsis asparagi	60.32 ug.mL-1
Antifungal activity against Magnaporthe oryzae by mycelium growth rate test	Magnaporthe oryzae	57.59 ug.mL-1
Antifungal activity against Rhizoctonia solani Kuhn by mycelium growth rate test	Rhizoctonia solani	56.13 ug.mL-1
Antifungal activity against Sclerotinia sclerotiorum by mycelium growth rate test	Sclerotinia sclerotiorum	533.29 ug.mL-1
Antifungal activity against Botryotinia fuckeliana by mycelium growth rate test	Botryotinia fuckeliana	19.86 ug.mL-1

Cross References

Resources	Reference
ChEMBL	CHEMBL2228289

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).